TLX
$8.32
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therape...
Recent News
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Investors Weigh Middle East War Signals, Oil Price Volatility
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively tr
Telix’s AI Imaging Moves And Glioma Filing Contrast With Valuation Discount
Telix Pharmaceuticals (ASX:TLX) announced a collaboration with University Hospital Essen to develop AI based prognostic models using PSMA PET imaging in prostate cancer. The company has also submitted a marketing authorization application in Europe for TLX101 Px, its glioma imaging candidate. Both updates relate to Telix's nuclear medicine pipeline and were reported ahead of routine earnings or guidance updates. Telix focuses on radiopharmaceuticals for cancer care, and these announcements...
Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After Recent Share Price Volatility
Telix Pharmaceuticals (ASX:TLX) has been drawing attention after recent share price volatility, with the stock showing mixed returns over the past month and past 3 months. This has prompted investors to reassess its radiopharmaceuticals exposure. See our latest analysis for Telix Pharmaceuticals. At the current A$9.76 share price, Telix has seen a 7.49% 30 day share price decline and a 32.46% 90 day share price decline, while the 1 year total shareholder return of 66.30% decline contrasts...
Is Telix Pharmaceuticals (ASX:TLX) Pricing Reflect Its Recent 66% One Year Share Price Slide
If you are wondering whether Telix Pharmaceuticals is starting to look attractively priced after a tough run, this article walks through what the current share price might be implying about its underlying value. The stock recently closed at A$9.76, with returns of 1.6% over 7 days, a 7.5% decline over 30 days, a 14.1% decline year to date, and a 66.3% decline over 1 year. The 3 year and 5 year returns sit at 34.3% and 174.2% respectively. These moves have come alongside ongoing investor...
Telix Pharmaceuticals Highlights $1B Revenue Track, Pixclara Resubmission, PSMA Growth at Oppenheimer Conf.
Telix Pharmaceuticals (NASDAQ:TLX) outlined its commercial imaging franchise, regulatory plans for two radiodiagnostic candidates, and progress across a broad therapeutic radiopharmaceutical pipeline during a discussion at Oppenheimer’s Annual Healthcare Conference with CEO Christian Behrenbruch. C